Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

Abstract Background Mutations in the KEAP1-NFE2L2 signaling pathway were linked to increased tumorigenesis and aggressiveness. Interestingly, not all hotspot mutations on NFE2L2 were damaging; some even were activating. However, there was conflicting evidence about the association between NFE2L2 mut...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Kewei Wang, Zixi Li, Ying Xuan, Yong Zhao, Chao Deng, Meidan Wang, Chenjun Xie, Fenglai Yuan, Qingfeng Pang, Wenjun Mao, Dongyan Cai, Zhangfeng Zhong, Jie Mei
Formatua: Artikulua
Hizkuntza:English
Argitaratua: BMC 2023-10-01
Saila:Cancer Cell International
Gaiak:
NFE2L2
NSCLC
Biomarker
NGS
Immunotherapy
Sarrera elektronikoa:https://doi.org/10.1186/s12935-023-03056-9

Antzeko izenburuak

Antzeko izenburuak